Company Reports Q1 Revenue of $27.5M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BLFS?
Reports Q1 revenue $27.5M, consensus $25.66M. "We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million," said CEO Roderick de Greef. "Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position, while high-margin, recurring revenue drives a strong financial profile. Our products are embedded across a significant portion of commercial therapies and clinical pipelines, and we are seeing continued momentum across the CGT landscape including expansion into larger indications, encouraging data readouts, renewed funding activity and strategic M&A. This positions us well for the next phase of growth in this market and we remain confident in our full year outlook."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLFS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLFS
Wall Street analysts forecast BLFS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.040
Low
32.00
Averages
33.25
High
34.00
Current: 22.040
Low
32.00
Averages
33.25
High
34.00
About BLFS
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLife Solutions Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BioLife Solutions reported Q1 2026 revenue of $27.5 million, reflecting a 25% year-over-year increase, indicating strong demand in the biopharmaceutical market, with full-year revenue guidance set between $112.5 million and $115 million, representing a growth of 17% to 20%.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $6.2 million in Q1, accounting for 22% of revenue, although gross margin declined due to bag yield dynamics; management remains optimistic about future profitability, viewing this decline as temporary.
- Stable Market Share: BPM products constitute over 85% of total revenue, with more than 70% market share in U.S. CGT clinical trials, underscoring the company's leadership position and sustained competitive advantage in the sector.
- Cash Flow Status: As of March 31, 2026, the company's cash and marketable securities balance was $111.5 million, down from $120.2 million as of December 31, 2025, primarily due to tax obligations and debt repayments, with management anticipating positive GAAP net income in 2026.
See More
BioLife Solutions Q1 Earnings Beat Expectations
- Strong Earnings Report: BioLife Solutions reported Q1 GAAP EPS of $0.02, beating expectations by $0.01, indicating the company's stable profitability amidst market fluctuations.
- Revenue Growth: The company achieved Q1 revenue of $27.5 million, reflecting a 15.1% year-over-year increase and surpassing market expectations by $1.84 million, showcasing its robust performance in the biopharmaceutical sector.
- 2026 Financial Guidance: BioLife reiterated its 2026 financial guidance, projecting revenue between $112.5 million and $115 million, representing a growth of 17% to 20% compared to 2025, demonstrating confidence in future expansion.
- Margin Outlook: The company anticipates GAAP and adjusted gross margins to remain in the mid-60% range, indicating ongoing improvements in cost management and profitability strategies.
See More
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
BioLife Solutions Reports Q4 Revenue of $24.8M, Up 20% Year-Over-Year
- Significant Revenue Growth: BioLife Solutions reported preliminary Q4 unaudited revenue from continuing operations of $24.8 million, reflecting a 20% year-over-year increase, which underscores the company's strong performance in the cell and gene therapy market and solidifies its market position.
- Full-Year Performance Exceeds Expectations: For FY2025, the company achieved $96.2 million in continuing operations revenue, surpassing the high end of previously raised guidance by 29%, indicating robust growth driven by its biopreservation product line and boosting investor confidence.
- Strategic Focus Transformation: Following the divestiture of the evo product line in 2025, BioLife is now positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises, which is expected to drive future profitability and long-term value creation.
- Optimistic Future Outlook: The company anticipates revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margins, indicating sustained competitiveness and profitability in the market.
See More
BioLife Solutions Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: BioLife Solutions reported Q1 2026 revenue of $27.5 million, reflecting a 25% year-over-year increase, indicating strong demand in the biopharmaceutical market, with full-year revenue guidance set between $112.5 million and $115 million, representing a growth of 17% to 20%.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $6.2 million in Q1, accounting for 22% of revenue, although gross margin declined due to bag yield dynamics; management remains optimistic about future profitability, viewing this decline as temporary.
- Stable Market Share: BPM products constitute over 85% of total revenue, with more than 70% market share in U.S. CGT clinical trials, underscoring the company's leadership position and sustained competitive advantage in the sector.
- Cash Flow Status: As of March 31, 2026, the company's cash and marketable securities balance was $111.5 million, down from $120.2 million as of December 31, 2025, primarily due to tax obligations and debt repayments, with management anticipating positive GAAP net income in 2026.
See More
BioLife Solutions Q1 Earnings Beat Expectations
- Strong Earnings Report: BioLife Solutions reported Q1 GAAP EPS of $0.02, beating expectations by $0.01, indicating the company's stable profitability amidst market fluctuations.
- Revenue Growth: The company achieved Q1 revenue of $27.5 million, reflecting a 15.1% year-over-year increase and surpassing market expectations by $1.84 million, showcasing its robust performance in the biopharmaceutical sector.
- 2026 Financial Guidance: BioLife reiterated its 2026 financial guidance, projecting revenue between $112.5 million and $115 million, representing a growth of 17% to 20% compared to 2025, demonstrating confidence in future expansion.
- Margin Outlook: The company anticipates GAAP and adjusted gross margins to remain in the mid-60% range, indicating ongoing improvements in cost management and profitability strategies.
See More
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
BioLife Solutions Reports Q4 Revenue of $24.8M, Up 20% Year-Over-Year
- Significant Revenue Growth: BioLife Solutions reported preliminary Q4 unaudited revenue from continuing operations of $24.8 million, reflecting a 20% year-over-year increase, which underscores the company's strong performance in the cell and gene therapy market and solidifies its market position.
- Full-Year Performance Exceeds Expectations: For FY2025, the company achieved $96.2 million in continuing operations revenue, surpassing the high end of previously raised guidance by 29%, indicating robust growth driven by its biopreservation product line and boosting investor confidence.
- Strategic Focus Transformation: Following the divestiture of the evo product line in 2025, BioLife is now positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises, which is expected to drive future profitability and long-term value creation.
- Optimistic Future Outlook: The company anticipates revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margins, indicating sustained competitiveness and profitability in the market.
See More
